Skip to main content
TipRanks
Go Ultimate75% OFF

Syndax Pharmaceuticals (SNDX) Revenue by Type

1,063 Followers

Revenue by Type

Syndax Pharmaceuticals reported revenue by type of $83.30M in Q3 2026, up 14.4% from Q2 2026 and up 81.6% year over year. This is the highest value since 2024.

Reveals how different revenue streams contribute to the overall income, highlighting the company’s diversification and potential reliance on specific products or services.

$0.00$20.00M$40.00M$60.00M$80.00MJun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Revenue mix has shifted from lumpy milestone/license receipts to steadily growing commercial Product and Collaboration streams, reflecting rapid Revuforj adoption and partner-reported Niktimvo traction; this transition increases recurring revenue visibility but Syndax's reported collaboration receipts materially trail partner sales due to contract terms. Milestone income remains episodic, so near-term quarters can still swing. Management’s guidance of sustained commercial momentum and a strong cash runway supports execution, but high ongoing R&D/SG&A and variability in new patient starts are the main risks to profitability timing.

SNDX Revenue by Type

PeriodProductCollaborationMilestone & LicenseTotal
Q3 2026Sep 30, 2026$60.74M$22.55M$0.00$83.30M
Q2 2026Jun 30, 2026$54.70M$18.09M$0.00$72.79M
Q1 2026Mar 31, 2026$48.92M$15.94M$0.00$64.86M
Q4 2025Dec 31, 2025$44.20M$19.39M$5.14M$68.73M
Q3 2025Sep 30, 2025$32.01M$13.86M$0.00$45.87M
Q2 2025Jun 30, 2025$28.60M$9.36M$0.00$37.96M
Q1 2025Mar 31, 2025$20.04M$0.00$0.00$20.04M
Q4 2024Dec 31, 2024$7.68M$0.00$0.00$7.68M
Q3 2024Sep 30, 2024$0.00$0.00$12.50M$12.50M
Q2 2024Jun 30, 2024$0.00$0.00$3.50M$3.50M

Related KPIs